Disentangling the PIGD classification for the prediction of cognitive impairment in de novo Parkinson’s disease

Daniele Urso\textsuperscript{1,2,3} · Valentina Leta\textsuperscript{1,2} · Lucia Batzu\textsuperscript{1,2} · Tayyabah Yousaf\textsuperscript{1} · Chloe Farrell\textsuperscript{1} · Daniel J. van Wamelen\textsuperscript{1,2,4} · K. Ray Chaudhuri\textsuperscript{1,2}

Received: 22 March 2021 / Revised: 19 July 2021 / Accepted: 26 July 2021 / Published online: 2 August 2021
© The Author(s) 2021

Abstract

Background Postural Instability and Gait difficulties (PIGD) subtype has been associated with worse cognitive performance in Parkinson’s disease (PD).

Objective To investigate whether PIGD subtype classification or PIGD-related clinical features predict the development of cognitive decline in de novo PD patients.

Methods Data from 422 PD patients with de novo PD were obtained from the PPMI database. At follow-up (up to 6 years), patients were categorized as having cognitive impairment or not. Multivariate Cox survival analysis was carried out including motor subtype and individual MDS-UPDRS items defining PIGD phenotype as predictors. Previously validated clinical predictors of cognitive impairment were included in the model as covariates. Occurrence of cognitive impairment at follow-up was used as the time-to-event and Kaplan–Meier curve was generated.

Results At baseline, 76 patients were classified as PIGD, 299 tremor-dominant and 47 as indeterminate. Development of cognitive impairment was not associated with PIGD subtype ($p = 0.252$). When individual MDS-UPDRS items were interrogated in the model, postural instability proved to be an independent predictor of cognitive impairment (HR = 2.045; 95%CI: 1.068–3.918; $p = 0.031$), while gait difficulties were not associated with cognitive decline ($p = 0.870$).

Conclusions Our findings suggest that postural instability, as assessed by MDS-UPDRS III, may serve as a possible indicator of the risk of developing cognitive impairment in de novo PD patients rather than the PIGD phenotype.

Keywords Parkinson’s disease · Cognitive impairment · Postural instability · PIGD

Introduction

Postural instability is a cardinal feature of Parkinson’s disease (PD), specifically in advanced motor stages [1]. Together with gait difficulties and freezing, it defines the motor subtype called ‘Postural Instability and Gait difficulties (PIGD)’ that has less favourable motor and non-motor outcomes and then the tremor-dominant (TD) subtype [2–4]. The classification in PIGD and TD subtypes is based on items from the Unified Parkinson’s Disease Rating Scale (UPDRS) [3, 5]. Compared with patients with the TD subtype, those with PIGD subtype are typically older, less responsive to levodopa and are more likely to develop motor fluctuations and dyskinesia, as well as exhibit a greater burden of non-motor symptoms and faster disease progression [6–8]. The PIGD phenotype has also been associated with worse cognitive performance in PD [3, 7, 9–11]. Pathological, neuroimaging, and biochemical evidence has justified...
the biological validity of this subtyping [12], with differences in amyloid-β distribution patterns potentially explaining the relationship between PIGD and cognitive impairment [13, 14].

However, some controversies exist on this topic, since many studies claimed no differences in long-term outcomes between these subtypes [15–18]. This variability can be explained given the instability of the classification of PD versus PIGD with patients shifting between phenotypic subtypes as the disease progresses [19], and approximately 20% of patients remaining unclassified as part of an intermediate subgroup [20]. In this respect, there have been some attempts to discriminate various phenotypes within the PIGD continuum [21].

Therefore, in this study, we aim to investigate whether PIGD phenotype classification or specific PIGD-related clinical features could predict the development of cognitive impairment after 6-year follow-up in a cohort of de novo PD patients.

**Methods**

**Participants**

We included 422 de novo PD patients from the Parkinson’s Progression Markers Initiative (PPMI) database. The PPMI is an ongoing prospective, observational, international, multicentre study aimed at identifying clinical biomarkers of PD in a large cohort of participants with early PD at enrolment [22]. The aims and methodology of the study have been extensively published elsewhere and are available at [www.ppmi-info.org/study-design](http://www.ppmi-info.org/study-design). Inclusion criteria were age 30 years or older, diagnosis of PD [based on the presence of one of the following: (1) asymmetrical resting tremor or (2) asymmetrical bradykinesia or (3) at least two of either of resting tremor, bradykinesia, and rigidity], as well as a disease duration of one to 24 months, Hoehn and Yahr (H&Y) stage of 1–2, and presence of striatal dopamine transporter deficit on 123I-ioflupane SPECT imaging (DaTSCAN). The study was approved by the institutional review board at each site, and participants provided written informed consent. We obtained data from the PPMI database in compliance with the PPMI Data Use Agreement on 2nd of December 2019.

**Clinical evaluation**

Data extracted from the PPMI database included demographics, age at onset, disease duration, as well as motor and non-motor symptom measures such as H&Y staging, Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) (including Part I-Non-Motor Aspects of Experiences of Daily Living, Part II-Motor Aspects of Experiences of Daily Living, and Part III-Motor Examination) [23], SCOPA-Autonomic (SCOPA-AUT) [24], Montreal Cognitive Assessment (MoCA) [25], University of Pennsylvania Smell Identification Test (UPSIT), Geriatric Depression Scale (GDS), State-Trait Anxiety Inventory (STAI), and REM Behavior Sleep Disorder questionnaire (RBDQuest). Neropsychological tests included Letter–Number Sequencing (working memory), Symbol-Digit Modalities Test (processing speed), animal fluency test (language/semantic fluency), Benton Judgment of Line Orientation 15-item (visuospatial functioning), and Hopkins Verbal Learning Test-Revised (HVLT, learning/mediate verbal memory and delayed verbal recall), 123I-FP-CIT striatal binding ratios, and cerebrospinal fluid (CSF) measures, specifically amyloid β 1–42 (Aβ1–42), total tau, and total α-synuclein were also extracted. At a follow-up of up to 6 years, patients were categorized as having normal cognition or cognitive impairment according to the PPMI protocol [22]. Cognitive impairment was defined as scores on two or more of the HVLT total recall, HVLT recognition discrimination, Benton Judgment of Line Orientation, Letter–Number Sequencing, semantic (animal) fluency test, or Symbol-Digit Modalities Test of more than 1.5 standard deviations below normal, regardless of the presence of functional impairment due to cognitive dysfunction. The cognitive categorization in PPMI was implemented at a later stage, meaning that many patients only have cognitive categorization from 2-year follow-up visit onwards. Since this information was not available at earlier time points, patients with at least two cognitive tests of more than 1.5 standard deviations below normal at baseline were considered as “suspected MCI”, to reflect the lower level of confidence in this classification [26]. At baseline, patients were grouped into TD subtype and PIGD subtype, based on the MDS-UPDRS scores [5].

**Statistical analysis**

Continuous variables were expressed as mean ± standard deviation, with between-group comparisons performed by one-way ANOVA or Mann–Whitney U test for normally or non-normally distributed variables, respectively. Categorical variables were expressed as proportions and compared using Pearson’s χ² test. Patients categorized having an indeterminate subtype were excluded from the analysis. Cox survival analyses were performed including, as predictors, motor subtype (TD versus PIGD), individual MDS-UPDRS items defining PIGD phenotype (Part II: item 12 “Balance and Walking” and item 13 “Freezing”, Part III: item 10 “Postural Instability” and 12 “Gait”), known predictors of cognitive impairment (age, sex, years of educations, MDS-UPDRS Part III, RBDQuest, CSF Aβ42, UPSIT, and 123I-FP-CIT caudate uptake) [17] as well as anticholinergic burden [27].
at univariate and multivariate levels. MDS-UPDRS Part III item 11 “Freezing of gait” was not included in the analysis as only three patients had this feature at baseline. The first occurrence of cognitive impairment at follow-up was used as the time-to-event in all Cox models. For these analyses, only patients with full cognitive testing on visits following baseline and without missing covariates were included. As the majority of patients’ first cognitive categorizations were made at the 2-year follow-up visit, there were 25 patients with MCI or PD dementia at their first categorization (up to the second year). As such, it is not possible to rule out that these patients did not already meet the criteria for MCI at baseline [26]. Thus, the Cox regression was repeated in a more restricted sample to assess whether postural instability was predictive of incident cognitive decline and did not depend on patients who may have had cognitively deteriorated at an earlier disease stage. In the repeated analysis, the criteria for “suspected MCI” (defined above) were applied at the baseline visit, and only participants without suspected MCI were included. Finally, Kaplan–Meier estimate and curve was generated, and comparisons were made using the log-rank (Mantel–Cox) test. Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS), version 25.0 (IBM Corp., Armonk, NY, USA). A p value of <0.05 was considered statistically significant and Benjamini–Hochberg procedure was used to correct in case of multiple testing.

Results

At baseline, 76 (18%) patients were classified having a PIGD subtype, 299 (71%) a TD subtype and 47 (11%) an indeterminate subtype. PIGD subtype patients had worse scores in activities of daily life (MDS-UPDRS Part II; p < 0.001) and H&Y scale (p = 0.023) compared with patients with TD subtype, and had a higher score of non-motor symptoms (MDS-UPDRS Part I; p = 0.008), specifically with higher anxiety (p < 0.004) and depression scores (p = 0.008) (Table 1). No other demographic or clinical differences were found between the groups. No differences were found in the detailed neuropsychological assessment, imaging, and CSF biomarkers.

During a median follow-up of 5 years (IQ range, 3–6 years), 79 patients developed cognitive impairment. 36.3% of patients with postural instability at baseline (MDS-UPDRS 3.12 item ≥ 1) developed cognitive impairment, while 18.3% of patient without postural instability at baseline developed cognitive impairment over a median follow-up of 5 years. Kaplan–Meier curve and log-rank (Mantel–Cox) test showed that PD patients with postural instability (MDS-UPDRS 3.12 item ≥ 1) have shorter cognitive impairment-free survival times over a median follow-up of 5 years when compared to the PD patients without Postural Instability (Log-Rank 9.607, p = 0.002, Fig. 1). In the univariate Cox proportional-hazard models, conversion to cognitive impairment from normal cognition was not associated with motor subtype [PIGD versus TD subtype; hazard ratio (HR) 1.395; 95% Confidence Interval (CI) 0.804–2.300; p = 0.252, Table 2], gait score (MDS-UPDRS Part II. item 10 ≥ 1; HR = 1.036; 95%CI: 0.666–1.616; p = 0.870), “Walking and Balances” (MDS-UPDRS Part II item 12 ≥ 1; HR = 1.063; 95%CI: 0.670–1.685; p = 0.372), or “Freezing” (MDS-UPDRS Part II. item 13 ≥ 1; HR = 0.500; 95%CI: 0.123–2.035; p = 0.372). Postural instability (MDS-UPDRS III. item 12 ≥ 1) was a significant predictor of cognitive impairment in both the univariate (HR = 2.510; 95%CI: 1.356–4.646; p = 0.003) and the multivariate model (HR = 2.045; 95%CI: 1.068–3.918; p = 0.031), the latter including known predictors of cognitive impairment (age, years of education, total MDS-UPDRS III score, RBDSQ, CSF Aβ42, UPSIT, and mean caudate dopaminergic uptake).

When restricting this analysis to only patients without “suspected MCI” at baseline, postural instability remained a significant predictor of cognitive impairment at both univariate (HR = 3.222; 95%CI: 1.498–6.931; p = 0.003, Table 3) and multivariate levels (HR = 2.573; 95%CI: 1.110–6.010; p = 0.029).

Discussion

Our findings suggest that motor subtyping based on TD/PIGD classification may not be relevant for the prediction of cognitive impairment in de novo PD patients as has been proposed in the previous studies. We would like to propose that postural instability alone, as assessed by the MDS-UPDRS Part III, may serve as a possible indicator for the risk of developing cognitive impairment.

The distinction between TD and PIGD is one of the most cited forms of PD subtyping. This motor subtype approach was conceptualized by Jankovic et al. [3] in their retrospective review of the DATATOP trial, using the ratio of tremor-related items on the UPDRS to PIGD-related items. This classification system was then adapted for the MDS-UPDRS motor scale [5] and has been extensively adopted in clinical trials and observational studies. The PIGD subtype has been associated with a higher burden of non-motor features than the TD subtype, particularly affective symptoms [8, 28]. This is in line with our baseline results, as we found that patients classified as PIGD subtype had a higher burden of non-motor symptoms, including worse anxiety and depression. PIGD has also been associated with the development of cognitive impairment and several studies have highlighted the relationship between PIGD severity and amyloid-β pathology through CSF measurement [29] or Positron Emission
Tomography (PET) imaging [13]. However, some studies have failed to demonstrate that this subtype was associated with the development of PD cognitive milestones [17]. Others have found that the transition between the TD to the PIGD phenotype, and not the baseline characterization, was able to predict the risk of dementia [30]. Simuni et al. [19] explored the stability of the TD/PIGD classification in an early untreated PD population, reporting that patients shifted bidirectionally between phenotypic subtypes as the disease progressed over the first year. Furthermore, many patients who had TD/PIGD ratios that fell close to the indeterminate range were eliminated from this categorization and further

### Table 1 Demographic and clinical features associated with TD/PIGD classification in patients with de novo Parkinson’s disease

| Demographic variables                  | TD (n = 299) | PIGD (n = 76) | p value |
|----------------------------------------|-------------|--------------|---------|
| Age                                    | 61.89 ± 9.47 | 61.91 ± 9.23 | 0.988   |
| Sex (male %)                           | 66.6%       | 61.8%        | 0.440   |
| Disease duration, months               | 6.76 ± 6.64 | 6.22 ± 5.48  | 0.841   |
| Age of onset, years                    | 59.75 ± 9.77 | 60.30 ± 9.54 | 0.572   |
| Age of diagnosis, years                | 61.33 ± 9.44 | 61.40 ± 9.22 | 0.958   |

| Clinical variables                     | TD (n = 299) | PIGD (n = 76) | p value |
|----------------------------------------|--------------|--------------|---------|
| MDS-UPDRS Part I                       | 5.17 ± 3.80  | 6.93 ± 4.75  | 0.008*  |
| MDS-UPDRS Part II                      | 5.27 ± 3.88  | 7.42 ± 4.57  | 0.00082*|
| MDS-UPDRS Part III                     | 21.14 ± 9.042| 21.00 ± 8.38 | 0.728   |
| H&Y stage 1, 2, and 3 (%)              | 46.5 ± 53.5  | 39.5 ± 57.9  | 0.0234* |
| UPSIT                                  | 22.16 ± 7.86 | 22.50 ± 9.43 | 0.782   |
| SCOPA-AUT                              | 9.31 ± 6.315 | 9.59 ± 5.48  | 0.565   |
| RBDSQ                                  | 4.02 ± 2.64  | 4.46 ± 2.94  | 0.480   |
| STAI                                   | 63.74 ± 18.12| 70.58 ± 17.49| 0.0045* |
| GDS                                    | 2.06 ± 2.24  | 3.24 ± 2.87  | 0.0078* |

| DaTSCAN                                |             |              |         |
|----------------------------------------|-------------|--------------|---------|
| Mean caudate                           | 2.01 ± 0.53 | 1.89 ± 0.63  | 0.067   |
| Mean putamen                           | 0.83 ± 0.27 | 0.79 ± 0.32  | 0.063   |
| Mean striatum                          | 1.42 ± 0.37 | 1.34 ± 0.45  | 0.079   |

| Neuropsychological assessment          | TD (n = 299) | PIGD (n = 76) | p value |
|----------------------------------------|--------------|--------------|---------|
| MoCA                                   | 27.08 ± 2.34 | 27.15 ± 2.43 | 0.799   |
| Benton judgment of line orientation    | 12.76 ± 2.13 | 12.61 ± 2.10 | 0.447   |
| Symbol digit modalities score          | 41.16 ± 9.83 | 40.58 ± 10.00| 0.771   |
| Semantic fluency total score           | 48.35 ± 11.43| 49.46 ± 13.41| 0.493   |
| Letter number sequencing raw score     | 10.55 ± 2.67 | 11.50 ± 2.73 | 0.842   |
| HVLT Immediate/total recall            | 24.46 ± 5.09 | 24.20 ± 4.888| 0.829   |
| HVLT delayed recall                    | 8.42 ± 2.48  | 8.03 ± 2.79  | 0.362   |
| HVLT delayed recognition               | 11.18 ± 1.30 | 11.14 ± 1.05 | 0.399   |
| HVLT false alarms                      | 1.30 ± 1.41  | 1.04 ± 0.93  | 0.493   |
| HVLT recognition discrimination        | 9.51 ± 2.87  | 10.07 ± 1.41 | 0.877   |
| HVLT retention                         | 0.86 ± 0.197 | 0.82 ± 0.23  | 0.206   |

| Data are presented as mean ± SD or percentage
| TD (n = 299) | PIGD (n = 76) | p value |
|--------------|--------------|---------|
| MoCA                                   | 27.08 ± 2.34 | 27.15 ± 2.43 | 0.799   |
| Benton judgment of line orientation    | 12.76 ± 2.13 | 12.61 ± 2.10 | 0.447   |
| Symbol digit modalities score          | 41.16 ± 9.83 | 40.58 ± 10.00| 0.771   |
| Semantic fluency total score           | 48.35 ± 11.43| 49.46 ± 13.41| 0.493   |
| Letter number sequencing raw score     | 10.55 ± 2.67 | 11.50 ± 2.73 | 0.842   |
| HVLT Immediate/total recall            | 24.46 ± 5.09 | 24.20 ± 4.888| 0.829   |
| HVLT delayed recall                    | 8.42 ± 2.48  | 8.03 ± 2.79  | 0.362   |
| HVLT delayed recognition               | 11.18 ± 1.30 | 11.14 ± 1.05 | 0.399   |
| HVLT false alarms                      | 1.30 ± 1.41  | 1.04 ± 0.93  | 0.493   |
| HVLT recognition discrimination        | 9.51 ± 2.87  | 10.07 ± 1.41 | 0.877   |
| HVLT retention                         | 0.86 ± 0.197 | 0.82 ± 0.23  | 0.206   |

| CSF variables                           | TD (n = 299) | PIGD (n = 76) | p value |
|----------------------------------------|--------------|--------------|---------|
| CSF Abeta1-42 (pg/mL)                   | 923.23 ± 427.65 | 888.01 ± 389.55 | 0.445   |
| CSF total synuclein (pg/mL)             | 1540.13 ± 682.46 | 1440.89 ± 615.12 | 0.220   |
| CSF total tau (pg/mL)                   | 171.84 ± 58.99  | 167.30 ± 53.06 | 0.660   |

*Significant p values after Benjamini–Hochberg correction for multiple testing.
Taking into consideration the above-mentioned issues, new arguments suggest that these motor phenotypes should not be assessed as discrete subtypes, but rather as a multi-dimensional continuum [31]. Our results showed that postural instability in itself may be an independent predictor of cognitive impairment in de novo PD patients, suggesting that disentangling the PIGD classification into individual items could be useful for predicting long-term development of PD cognitive milestones, especially in the very early phases of PD, when patients' motor features have not yet “matured” [19]. As such, it may be argued that motor subtyping in de novo PD cannot be reliably performed and should not be used in predictive studies, and that individual MDS-UPDRS items may prove more useful as predictors for later outcome. Addition of non-motor subtyping, as has been proposed based on cluster analysis [32, 33] as well as clinical phenotyping [34], should also be considered.

Table 2  Results of the Cox proportional-hazards analysis for the predictors of cognitive impairment

| Variables                          | Univariable analysis | Multivariable analysis |
|-----------------------------------|----------------------|------------------------|
|                                   | HR (95% CI)          | p value                | HR (95% CI)          | p value    |
| Motor subtype (PIGD versus TD)    | 1.359 (0.804–2.300)  | 0.252                  | –                      | –          |
| Walking and balance               | 1.063 (0.670–1.685)  | 0.372                  | –                      | –          |
| Freezing                          | 0.500 (0.123–2.035)  | 0.333                  | –                      | –          |
| Gait                              | 1.038 (0.666–1.616)  | 0.870                  | –                      | –          |
| Postural instability              | 2.510 (1.356–4.646)  | 0.003                  | 2.045 (1.068–3.918)   | 0.031      |
| Age                               | 1.067 (1.039–1.094)  | <0.001                 | 1.053 (1.023–1.084)   | 0.001      |
| Genre                             | 1.646 (0.983–2.758)  | 0.058                  | 0.922 (0.529–1.610)   | 0.776      |
| Education (years)                 | 0.933 (0.864–1.008)  | 0.077                  | 0.925 (0.855–1.002)   | 0.056      |
| MDS-UPDRS III                     | 1.038 (1.014–1.063)  | 0.002                  | 1.029 (1.002–1.057)   | 0.034      |
| RBDSQ                             | 2.267 (1.456–3.531)  | <0.001                 | 1.783 (1.120–2.839)   | 0.015      |
| CSF Aβ42 (log)                    | 0.081 (0.024–0.274)  | <0.001                 | 0.096 (0.027–0.339)   | <0.001     |
| UPSIT                             | 0.930 (0.904–0.957)  | <0.001                 | 0.957 (0.928–0.986)   | 0.05       |
| Mean caudate uptake               | 0.366 (0.237–0.565)  | <0.001                 | 0.561 (0.349–0.901)   | 0.015      |
| ACB score                         | 1.359 (0.870–2.122)  | 0.177                  | –                      | –          |

MDS-UPDRS Unified Parkinson’s Disease Rating Scale, MoCA Montreal cognitive assessment, RBDSQ REM Sleep Behavior Disorder Questionnaire Score, UPSIT University of Pennsylvania Smell Identification Test, CSF cerebrospinal fluid, Aβ42 amyloid β 1–42

Based on UPDRS part II items
Based on UPDRS part III items
To avoid collinearity, the items relative to “Postural Instability”, “Freezing”, and “Gait” were excluded by the UPDRS 3 total score
Postural instability is a cardinal feature in PD [1] and is a key staging marker on the modified Hoehn and Yahr scale [35] marking the transition from early, mild disease to late, severe disease. Being relatively uncommon in the early stage of the disease course, one could hypothesise that postural instability might be a more sensitive predictor of worse long-term outcomes, such as cognitive impairment. Postural instability is usually clinically documented using the quick and easy retropulsion test (Pull Test, MDS-UPDRS Part III item 12). Postural and balance deficits in PD may result from lesions to both dopaminergic and non-dopaminergic nuclei [36]. The impaired cholinergic transmission in the pedunculopontine nucleus (PPN), known to degenerate in PD [37, 38], has shown to be implicated in the occurrence of postural instability [39], impinging on the attentional control of posture and detection of movement errors [40]. Interestingly, cholinergic perturbations have also been robustly associated with cognitive impairment in PD [41].

On the other hand, our results showed that gait difficulties do not predict cognitive impairment in early PD. Of note, gait difficulties in PD are multifactorial in nature and common comorbidities like peripheral neuropathy and osteo-arthritis, can further impair this motor feature [42]. To some extent, every aspect of gait evaluated through the MDS-UPDRS item has a substantial dopaminergic-related component (“velocity and step length stride amplitude, stride speed, height of foot lift, heel strike during walking, turning, and arm swing”) that can be directly related to rigidity or bradykinesia, especially during the early stage. These observations indicate that gait difficulties, as conventionally evaluated, are less sensitive than postural instability in identifying early PD patients with a more extensive (extranigral, non-dopaminergic) underlying pathology and thus more prone to develop cognitive impairment.

Limitations of our study include the use of subjective outcome measures characterized by limited reliability compared to objective device-based motor data. Nevertheless, the MDS-UPDRS represents a validated and easy-to-use tool that can be used in clinical settings. Second, we did not evaluate how the severity of postural instability was correlated to the longitudinal outcomes. Nevertheless, since this motor feature is less common in the early stage of PD, in our analyses, we focused on its presence or absence as a categorical variable, to define a subgroup of de novo patients experiencing this symptom even with a mild severity. Finally, we should mention that PPMI neuropsychological battery only allows a Level I classification of cognitive impairment that is less sensible and more prone to false-negative findings compared to the Level II classification, which requires two tests within each of the five cognitive domains (i.e., attention and working memory, executive, language, memory, and visuospatial) [43].

| Variables | Univariable analysis | Multivariable analysis |
|-----------|----------------------|------------------------|
|           | HR (95% CI)          | p value    | HR (95% CI) | p value |
| Motor subtype (PIGD versus TD) | 0.813 (0.412–1.605) | 0.551 | – | – |
| Walking and balance | 1.077 (0.579–2.003) | 0.814 | – | – |
| Freezinga* | 0.047 (0.001–27.792) | 0.347 | – | – |
| Gaitb | 0.841 (0.469–1.508) | 0.584 | – | – |
| Postural instabilityb | 3.222 (1.498–6.931) | 0.003 | 2.573 (1.110–6.010) | 0.029 |
| Age | 1.084 (1.046–1.123) | <0.001 | 1.075 (1.032–1.120) | <0.001 |
| Genre | 0.659 (0.341–1.277) | 0.217 | – | – |
| Education (years) | 0.924 (0.828–1.031) | 0.158 | 0.939 (0.838–1.052) | 0.279 |
| MDS-UPDRS IIIc | 1.030 (0.997–1.063) | 0.074 | 1.044 (1.015–1.074) | 0.003 |
| RBDSQ | 1.983 (1.105–3.557) | 0.022 | 1.157 (0.846–2.943) | 0.152 |
| CSF Aβ42 (log) | 0.108 (0.021–0.543) | 0.108 | 0.131 (0.025–0.702) | 0.018 |
| UPSIT | 0.931 (0.897–0.966) | <0.001 | 0.955 (0.920–0.992) | 0.018 |
| Mean caudate uptake | 0.238 (0.131–0.434) | <0.001 | 0.356 (0.186–0.681) | 0.002 |
| ACB score | 1.268 (0.699–2.304) | 0.435 | – | – |

PD patients with “Suspected MCI” at baseline have been excluded from this analysis

MDS-UPDRS Unified Parkinson’s Disease Rating Scale, MoCA Montreal cognitive assessment, RBDSQ REM Sleep Behavior Disorder Questionnaire Score, UPSIT University of Pennsylvania Smell Identification Test, CSF cerebrospinal fluid, Aβ42 amyloid β 1–42

a Based on UPDRS part II items
b Based on UPDRS part III items
c To avoid the collinearity, the items relative to “Postural Instability”, “Freezing”, and “Gait” were excluded by the UPDRS 3 total score
In conclusion, our results suggest that postural instability, but not gait difficulties or the TD/PIGD motor subtyping, may be appropriate for the prognostication of cognitive impairment in early de novo PD and emphasize the need for greater vigilance in this subgroup of patients.

Acknowledgements Data used in the preparation of this article were obtained from the Parkinson’s Progression Markers Initiative (PPMI) database (www.ppmi-info.org/data). For up-to-date information on the study, visit www.ppmi-info.org. PPMI (a public–private partnership) is funded by the Michael J Fox Foundation for Parkinson’s Research and funding partners, including AbbVie, Avid, Biogen, Bristol-Myers Squibb, Covance, GE Healthcare, Genentech, GlaxoSmithKline, Lilly, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Roche, Servier, Teva, and UCB. The current data analysis was not supported by funding. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The authors acknowledge the support of the NIHR London South Clinical Research Network and the NIHR Biomedical Research Centre. This article represents independent collaborative research part funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The authors acknowledge the support of the NIHR London South Clinical Research Network and the NIHR Biomedical Research Centre. This article represents independent collaborative research part funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London.

Author contributions DU: conception and design of the study; analysis and interpretation of data; writing the first draft. VL: interpretation of data; critical revision for important intellectual content. LB: interpretation of data; critical revision for important intellectual content. TY: analysis and interpretation of data, revising the manuscript for content. CF: revising the manuscript for content. DwW: interpretation of data, revising the manuscript for content. KRC: conception and design of the study; analysis and interpretation of data; revising the manuscript for content. All the co-authors listed above gave their final approval of this manuscript version.

Funding DU, LB, TY, and CF have no disclosures. VL has received grants from BRC, Parkinson’s UK, a travel and congress grant from Bial UK Ltd, speaker-related activities fees from Britannia Pharmaceuticals, and consultancy fees from Invisio Pharmaceuticals, outside the submitted work. DwW reports grants, speaker fees, and honoraria from Britannia Pharmaceuticals Ltd, speaker fees from Abbvie UK Ltd, and honoraria from Invisio Pharmaceuticals, outside of the submitted work. KRC has received honoraria for Advisory board from AbbVie, UCB, GKC, Bial, Cygnus, Novartis, Lobsor, Stada, Medtronic, Zambon, Profile, Sunovion, Roche, Theravance, Scion, Britannia; honoraria for lectures from AbbVie, Britannia, UCB, Mundipharma, Zambon, Novartis, Boeringer Ingelheim; Grants (Investigator Initiated) from Britannia Pharmaceuticals, AbbVie, UCB, GKC, Bial; Academic grants from EU, IMI EU, Horizon 2020, Parkinson’s UK, NIHR, PDMRI, EU (Horizon 2020), Kirby Laing Foundation, NPF; MRC, Wellcome Trust, outside of the submitted work.

Declarations

Conflicts of interest The authors declare that there are no conflicts of interest relevant to this work.

Ethical approval The study was approved by the institutional review board at each site (www.ppmi-info.org), and participants provided written informed consent. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386(9996):986–912
2. Zettsusky WJ, Jankovic J, Pirozzolo FJ (1985) The heterogeneity of parkinsonian disease: clinical and prognostic implications. Neurology 35(4):522–526
3. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L et al (1990) Variable expression of Parkinson’s disease. a base-line analysis of the DATATOP cohort. Neurology 40(10):1529
4. Aleksovsky D, Miljkovic D, Bravi D, Antonini A (2018) Disease progression in Parkinson subtypes: the PPMI dataset. Neuror Sci 39(11):1971–1976
5. Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC (2013) How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: comparison with the unified Parkinson’s disease rating scale. Mov Disord 28(5):668–670
6. Thenganatt MA, Jankovic J (2014) Parkinson disease subtypes. JAMA Neurol 71(4):499–504
7. Van Der Heeden JF, Marinus J, Martinez-Martín P, Rodriguez-Blazquez C, Geraeds VJ, Vi Hiltun JJ (2016) Postural instability and gait are associated with severity and prognosis of Parkinson disease. Neurology 86(24):2243–2250
8. Marras C, Chaudhuri KR (2016) Nonmotor series: nonmotor features of Parkinson’s disease subtypes. Mov Disord 31(8):1095–1102
9. Choi SM, Kim BC, Cho BH, Kang KW, Choi KH, Kim JT et al (2018) Comparison of two motor subtype classifications in de novo Parkinson’s disease. Parkinsonism Relat Disord 54(January 2011):74–78
10. Burn DJ, Rowan EN, Allan LM, Molloy S, O’Brien JT, McKeith IG (2006) Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 77(5):585–589
11. Williams-Gray CH, Foltynie T, Brayne CEG, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 130(7):1787–1798
12. Marras C (2015) Subtypes of Parkinson’s disease: state of the field and future directions. Curr Opin Neurol 28(4):382–386
13. Möller MLTM, Frey KA, Petrou M, Kotagal V, Koepp RA, Albin RL et al (2013) β-amyloid and postural instability and gait difficulty in Parkinson’s disease at risk for dementia. Mov Disord 28(3):296–301
14. Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Cappel C, Cohey CS et al (2013) Association of cerebrospinal fluid β-amyloid
1–42, t-tau, p-tau 181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70(10):1277–1287

15. Lee JW, Song YS, Kim H, Ku BD, Lee WW (2019) Alteration of tremor dominant and postural instability gait difficulty subtypes during the progression of Parkinson’s disease: analysis of the PPMI cohort. Front Neurol 10(MAY):1–8

16. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ (2009) A clinico-pathological study of subtypes in Parkinson’s disease. Brain 132(11):2947–2957

17. Schrag A, Siddiqi UF, Anastasiou Z, Weintraub D, Schott JM (2017) Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson’s disease: a cohort study. Lancet Neurol 16(1):66

18. Johnson AR, Bucks RS, Kane RT, Thomas MG, Gasson N, Loftus AM (2016) Motor subtype as a predictor of future working memory performance in idiopathic Parkinson’s disease. PLoS ONE 11(3):e0152534

19. Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Tanner C, Marek K (2016) How stable are Parkinson’s disease subtypes in de novo patients: Analysis of the PPMI cohort? Parkinsonism Relat Disord 28:62–67

20. Konno T, Deutschländer A, Heckman MG, Ossi M, Vargas ER, Strongosky AJ et al. (2018) Comparison of clinical features among Parkinson’s disease subtypes: a large retrospective study in a single center. J Neurol Sci 386(October 2017):39–45

21. Factor SA, Kyle Steenland N, Higgins DS, Molho ES, Kay DM, Montimurro J et al. (2011) Postural instability/gait disturbance in Parkinson’s disease has distinct subtypes: an exploratory analysis. J Neurol Neurosurg Psychiatry 82(5):564–568

22. Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T et al. (2011) The Parkinson progression marker initiative (PPMI). Prog Neurobiol 95(4):629–635

23. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al. (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19(9):1020–1028

24. Bloom BR, Beckley DJ, Gert Van Dijk J, Zwinderman AH, Remler MP, Roos RAC (1996) Influence of dopaminergic medication on automatic postural responses and balance impairment in Parkinson’s disease. Mov Disord 11(5):509–521

25. Bohnen NI, Müller MLTM, Koeppke RA, Studenski SA, Kilbourn MA, Frey KA et al. (2009) History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 73(20):1670–1676

26. Welte ML, Demain A, Ewenczyk C, Czernecki V, Lau B, El Helou A et al. (2015) PPNa-DBS for gait and balance disorders in Parkinson’s disease: a double-blind, randomised study. J Neurol 262(6):1215–1224

27. Visser M, Marinus J, Stiggelbout AM, Van Hilten JN (2004) Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov Disord 19(11):1306–1312

28. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I et al. (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695–699

29. Ray NJ, Bradburn S, Murgatroyd C, Toseeb U, Mir P, Kourentiotis GK et al. (2018) In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson’s disease. Brain 141(1):165–176

30. Weintraub D, Caspell-Garcia C, Simuni T, Cho HR, Coffey CS, Aarsland D et al. (2020) Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. Ann Clin Transl Neurol 7(4):449–461

31. Reijnders JSAM, Ehrt U, Lousberg R, Aarsland D, Leentjens AFG (2009) The association between motor subtypes and psychopathology in Parkinson’s disease. Parkinsonism Relat Disord 15(5):379–382

32. Alves G, Pedersen KF, Bloem BR, Blennow K, Zetterberg H, Borm GF et al. (2013) Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson’s disease. J Neurol Neurosurg Psychiatry 84(5):537–543

33. Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D (2006) Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord 21(8):1123–1130

34. Kotagal V (2016) Is PIGD a legitimate motor subtype in Parkinson disease? Ann Clin Transl Neurol 3(6):473–477

35. Martinez-Martín P, Rojo-Abuín JM, Weintraub D, Chaudhuri KR, Rodriguez-Blázquez C, Rizos A et al. (2020) Factor analysis and clustering of the movement disorder society-non-motor rating scale. Mov Disord 35(6):969–975

36. Mu J, Chaudhuri KR, Bielza C, de Pedro-Cuesta J, Larrañaga P, Martinez-Martin P (2017) Parkinson’s disease subtypes identified from cluster analysis of motor and non-motor symptoms. Front Aging Neurosci 9:301

37. Sauerbier A, Jenner P, Todorova A, Chaudhuri KR (2016) Non motor subtypes and Parkinson’s disease. Parkinsonism Relat Disord 22(Suppl 1):S41–S46

38. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C et al. (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19(9):1020–1028

39. Borm GF et al. (2013) Cerebrospinal fluid amyloid-β and p-tau, p-tau 181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70(10):1277–1287

40. Sarter M, Albin RL, Kucinski A, Lustig C (2014) Where attention goes, memory follows: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function. Exp Neurol 257:120–129

41. Aarsland D, Creese B, Politis M, Chaudhuri KR, Dominic H, Petersen RC et al. (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement Disorder Society Task Force guidelines. Mov Disord 27(3):349–356